Immunoradiometric assay for human complement component C9 utilising monoclonal antibodies.

A two-site immunoradiometric assay for human C9 has been developed. The assay utilised two non-competing monoclonal antibodies to C9 in a single incubation assay protocol. The detection limit of the assay was 0.1 ng (1.4 X 10(-15) moles) in a sample volume of 100 microliters. Using this assay the C9 concentration in normal human plasma was 60.2 +/- 14.9 mg/l (mean +/- 1 standard deviation, 8.5 X 10(-10) mol/l. Significantly elevated levels were found in the plasma of patients with rheumatoid arthritis (90.4 +/- 19.9 mg/l, mean +/- 1 SD). Measurements of C9 in cerebrospinal fluid and synovial fluid were also performed. The low levels of C9 in cerebrospinal fluid (less than 1 mg/l), undetectable by previously available assay methods, were easily measurable with this highly sensitive assay.